News

Influenza, COVID-19 are trigger events for aHUS in man, 19

Two infections — influenza followed by COVID-19 — were trigger events for separate episodes of atypical hemolytic uremic syndrome (aHUS) in a young man in Japan, a case study reports. The researchers noted that the man’s “[two] episodes of recurrent aHUS following respiratory tract infections” resolved without the need…

Scientists urge heart screening for aHUS patients

Pericardial effusion — a potentially life-threatening disorder marked by the buildup of fluid around the heart — can affect people with atypical hemolytic uremic syndrome (aHUS), though it may not cause obvious symptoms, and aHUS patients should be screened for it, scientists said. The scientists, after reading a…

For Awareness Day 2025, advocates to focus on ways to manage aHUS

For this year’s aHUS Awareness Day — held annually on Sept. 24 — advocates worldwide will focus on managing the rare disease, asking people with atypical hemolytic uremic syndrome (aHUS) to share the single best decision they’ve made regarding their care. “Atypical hemolytic uremic syndrome impacts every aspect of…

Switching from Soliris to Ultomiris is safe after kidney transplant

People with atypical hemolytic uremic syndrome (aHUS) who’ve had a kidney transplant can safely switch from Soliris (eculizumab) to Ultomiris (ravulizumab-cwvz) without risking a recurrence of the disease. That’s according to a real-world study that also found that blood and kidney-related disease markers remained stable after the switch, and…

Soliris eases woman’s disease symptoms after flu triggers aHUS

Soliris (eculizumab) helped ease disease symptoms for a woman with multiple myeloma who developed atypical hemolytic uremic syndrome (aHUS) as a complication of a viral infection caused by H1N1 influenza — also known as influenza A, or swine flu. “The prompt recognition and initiation of anti-complement therapy played…

Soliris withdrawal possible in aHUS with careful monitoring: Study

Most people with atypical hemolytic uremic syndrome (aHUS) who are stable on Soliris (eculizumab) can stop treatment after at least six months without having a relapse, provided that they’re carefully monitored, a recent study reported. Scientists expect that this could prevent treatment-related complications and burden for patients, while…

Soliris treats pregnancy-related aHUS in woman with CFH mutation

A 38-year-old woman who developed pregnancy-associated atypical hemolytic uremic syndrome (P-aHUS) after giving birth via cesarean section successfully recovered following treatment with Soliris (eculizumab), a case report from China shows. Genetic testing revealed the presence of a mutation in the CFH gene, which likely contributed to her condition.